CellWell record HH-147647
Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria
Ana Checa-Ros; Owahabanun Joshua Okojie; Jacob Gabriel Wassouf; Aida Yedean; Wei-Chung Hsueh; Patryk Hebda; Esther Rodriguez Llobell; Greta Bianca Muhmenthaler; Martin Duc-Duy Tran; Luis D'Marco
2026
In plain language
Glucagon-like peptide-1 receptor agonists reduce albuminuria and slow diabetic kidney disease progression through multiple mechanisms including weight loss, blood pressure reduction, and anti-inflammatory effects.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-147647
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.